Legend Biotech (Legend Biotech) Additional Paid-In Capital : $2,645.9 Mil(As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Legend Biotech Additional Paid-In Capital?

Legend Biotech's quarterly additional paid-in capital increased from Sep. 2023 ($2,633.9 Mil) to Dec. 2023 ($2,637.1 Mil) and increased from Dec. 2023 ($2,637.1 Mil) to Mar. 2024 ($2,645.9 Mil).

Legend Biotech's annual additional paid-in capital increased from Dec. 2021 ($1,261.5 Mil) to Dec. 2022 ($1,657.0 Mil) and increased from Dec. 2022 ($1,657.0 Mil) to Dec. 2023 ($2,637.1 Mil).

Legend Biotech Additional Paid-In Capital Historical Data

The historical data trend for Legend Biotech's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Legend Biotech Additional Paid-In Capital Chart

Legend Biotech Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

3.91

708.31

1,261.45

1,657.02

2,637.12

Legend Biotech Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial															-	-	2,633.91	2,637.12	2,645.87

Legend Biotech Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Legend Biotech Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Legend Biotech's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Legend Biotech (Legend Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Legend Biotech Corp (NAS:LEGN) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

9LB:Germany

Address

2101 Cottontail Lane, Somerset, NJ, USA, 08873

Website

https://www.legendbiotech.com

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy is for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America.